Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?

A recently discovered haplotype- -determines the ultrarapid metabolism of several CYP2C19 substrates. The platelet inhibitor clopidogrel requires CYP2C19-mediated activation: the risk of ischemic events is increased in patients with a poor (PM) or intermediate (IM) CYP2C19 metabolizer phenotype (vs....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Genes 2024-05, Vol.15 (5), p.607
Hauptverfasser:	Ganoci, Lana, Palić, Jozefina, Trkulja, Vladimir, Starčević, Katarina, Šimičević, Livija, Božina, Nada, Lovrić-Benčić, Martina, Poljaković, Zdravka, Božina, Tamara
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angioplasty Bleeding Blood platelets Clopidogrel Clopidogrel - adverse effects Clopidogrel - therapeutic use Cytochrome P-450 CYP2C19 - genetics Embolization Enzymes Female Genotype Genotype & phenotype Genotypes Haplotypes Hemorrhage - chemically induced Hemorrhage - genetics Humans Ischemia Male Medical laboratories Metabolism Metabolites Middle Aged Phenotypes Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Stroke Ticlopidine - adverse effects Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!